Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 8/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10028360 | 0.85 | CYP19A1 (0.45) | CYP19A1CYP17A1TDP1PTPN2PTPN1 | |
| SCHEMBL498347 | 0.85 | CYP19A1 (0.45) | CYP19A1CYP17A1TDP1PTPN2PTPN1 | |
| SCHEMBL2297940 | 0.79 | MEN1 (0.46) | PTPN2PTPN1PTPRBACP1MEN1 | |
| SCHEMBL498335 | 0.79 | CYP19A1 (0.43) | CYP19A1KMT2A | |
| SCHEMBL498400 | 0.79 | CYP19A1 (0.43) | CYP19A1MEN1KMT2A | |
| SCHEMBL2300846 | 0.76 | MEN1 (0.47) | PTPN2PTPN1PTPRBACP1MEN1 | |
| SCHEMBL8727726 | 0.74 | MEN1 (0.49) | PTPN2PTPN1PTPRBACP1MEN1 | |
| SCHEMBL498334 | 0.70 | PTPN2 (0.41) | PTPN2PTPN1PTPRBACP1MEN1 | |
| SCHEMBL498355 | 0.70 | CYP19A1 (0.42) | CYP19A1MEN1KMT2A | |
| SCHEMBL4338395 | 0.70 | CYP19A1 (0.46) | CYP19A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106230-B2 | Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8030486-B2 | Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20110046373-A1 | SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION | INAGAKI TAKASHI | 2011-02-24 | — | — | US | disclosed |
| US-20100076203-A1 | Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046373-A1 | SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION | SUCNR1, DLST, SHMT2 | CYP19A1 533/4885CYP17A1 827/4885TDP1 4164/4885 |
| US-20100076203-A1 | Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation | SUCNR1, DLST, SHMT2 | CYP19A1 533/4885CYP17A1 827/4885TDP1 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.